The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Learn how psoriasis, allergies, and eczema are connected and how they're different. Get lifestyle tips on managing both.

A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Risankizumab is effective through 2.5 years of treatment among patients with psoriasis, with most patients achieving rapid and sustained response.

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

Phase 3 trial results show combined ixekizumab and tirzepatide therapy outperforms ixekizumab alone for patients with psoriasis and obesity or overweight.

Portia has not taken Sotyktu. Portia Brown* has long been drawn toward helping people cope with challenges. Since volunteering as a college student to work with her peers to educate them about sexual ...

Psoriasis can easily be mistaken for other difficult-to-deal-with skin problems, like a bad infection or rash, eczema, or dermatitis. And because it varies in severity, it can be tricky to figure out ...